Other complications and associated conditions

Pediatric Diabetes

Volumn 8, Issue 3, 2007, Pages 171-176

  Kordonouri, Olga ^a   Maguire, Ann M ^a   Knip, Mikael ^a   Schober, Edith ^a   Lorini, Renata ^a   Holl, Reinhard W ^a   Donaghue, Kim C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AUTOANTIBODY; AUTOIMMUNE REGULATOR PROTEIN; BECAPLERMIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBIMAZOLE; CYCLOSPORIN; ENDOMYSIUM ANTIBODY; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH HORMONE; HEMOGLOBIN A1C; IMMUNOGLOBULIN A; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; LEVOTHYROXINE; MINERALOCORTICOID; MYCOPHENOLIC ACID; OXYGEN; PROPYLTHIOURACIL; PSORALEN; SOMATOMEDIN C; STEROID; THYROID ANTIBODY; THYROTROPIN; THYROXINE;

ADDISON DISEASE; AGITATION; ARTHROPATHY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; CARDIOVASCULAR RISK; CELIAC DISEASE; CHILD DEVELOPMENT; CHROMOSOME 21; DIABETES CONTROL; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; EDEMA; FAMILIAL DISEASE; GENE MUTATION; GLUTEN FREE DIET; GROWTH RETARDATION; HEMOGLOBIN DETERMINATION; HORMONE SUBSTITUTION; HUMAN; HYPERANDROGENISM; HYPERBARIC OXYGEN; HYPERTHYROIDISM; HYPOTHYROIDISM; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE BIOPSY; LASER SURGERY; LIPOATROPHY; LIPOHYPERTROPHY; NECROBIOSIS LIPOIDICA; OBESITY; OVARY POLYCYSTIC DISEASE; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; SKIN GRAFT; TACHYCARDIA; THYROID SURGERY; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT CONTRAINDICATION; ULTRAVIOLET A RADIATION; VITILIGO; WEIGHT GAIN; CHILD; GROWTH DISORDER; PATIENT CARE PLANNING; STANDARD; THYROID DISEASE;

ADDISON DISEASE; AUTOIMMUNE DISEASES; CELIAC DISEASE; CHILD; DIABETES MELLITUS, TYPE 1; GROWTH DISORDERS; HUMANS; JOINT DISEASES; PATIENT CARE PLANNING; THYROID DISEASES;

EID: 34249883883     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/j.1399-5448.2007.00249.x     Document Type: Article

References (81)

1. Bognetti E, Riva MC, Bonfanti R, Meschi F, Viscardi M, Chiumello G. Growth changes in children and adolescents with short-term diabetes. Diabetes Care 1998: 21: 1226-1229.
2. Donaghue KC, Kordonouri O, Chan A, Silink M. Secular trends in growth in diabetes: Are we winning? Arch Dis Child 2003: 88: 151-154.
3. Gunczler P, Lanes R. Poor metabolic control decreases the growth velocity of diabetic children. Diabetes Care 1999: 22: 1012.
4. Holl RW, Grabert M, Heinze E, Sorgo W, Debatin KM. Age at onset and long-term metabolic control affect height in type-1 diabetes mellitus. Eur J Pediatr 1998: 157: 972-977.
5. Holl RW, Heinze E, Seifert M, Grabert M, Teller WM. Longitudinal analysis of somatic development in paediatric patients with IDDM: genetic influences on height and weight. Diabetologia 1994: 37: 925-929.
6. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993: 329: 977-986.
7. Holl RW, Grabert M, Sorgo W, Heinze E, Debatin KM. Contributions of age, gender and insulin administration to weight gain in subjects with IDDM. Diabetologia 1998: 41: 542-547.
8. Thon A, Heinze E, Feilen KD et al. Development of height and weight in children with diabetes mellitus: Report on two prospective multicentre studies, one cross-sectional, one longitudinal. Eur J Pediatr 1992: 151: 258-262.
9. Codner E, Soto N, Lopez P et al. Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2006: 91: 2250-2256.
10. Atkinson MA, Eisenbarth GS. Type 1 diabetes: New perspectives on disease pathogenesis and treatment. Lancet 2001: 358: 221-229.
11. Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med 2004: 350: 2068-2079.
12. Sougioultzoglou F, Falorni A, Kassi G, Brozzetti A, Karamitsos D, Koliakos GG. Coincidence of high antiislet and antithyroid autoantibody titles in first-degree relatives of patients with type 1 diabetes. Exp Clin Endocrinol Diabetes 2005: 113: 85-89.
13. Sumnik Z, Kolouskova S, Malcova H et al. High prevalence of coeliac disease in siblings of children with type 1 diabetes. Eur J Pediatr 2005: 164: 9-12.
14. Hansen D, Bennedbaek FN, Hoier-Madsen M, Hegedus L, Jacobsen BB. A prospective study of thyroid function, morphology and autoimmunity in young patients with type 1 diabetes. Eur J Endocrinol 2003: 148: 245-251.
15. Glastras SJ, Craig ME, Verge CF, Chan AK, Cusumano JM, Donaghue KC. The role of autoimmunity at diagnosis of type 1 diabetes in the development of thyroid and celiac disease and microvascular complications. Diabetes Care 2005: 28: 2170-2175.
16. De Block CE, De Leeuw IH, Vertommen JJ et al. Beta-cell, thyroid, gastric, adrenal and coeliac autoimmunity and HLA-DQ types in type 1 diabetes. Clin Exp Immunol 2001: 126: 236-241.
17. Holl RW, Bohm B, Loos U, Grabert M, Heinze E, Homoki J. Thyroid autoimmunity in children and adolescents with type 1 diabetes mellitus. Effect of age, gender and HLA type. Horm Res 1999: 52: 113-118.
18. Kontiainen S, Schlenzka A, Koskimies S, Rilva A, Maenpaa J. Autoantibodies and autoimmune diseases in young diabetics. Diabetes Res 1990: 13: 151-156.
19. Kordonouri O, Klinghammer A, Lang EB, Gruters-Kieslich A, Grabert M, Holl RW. Thyroid autoimmunity in children and adolescents with type 1 diabetes: A multicenter survey. Diabetes Care 2002: 25: 1346-1350.
20. Kordonouri O, Hartmann R, Deiss D, Wilms M, Gruters-Kieslich A. Natural course of autoimmune thyroiditis in type 1 diabetes: Association with gender, age, diabetes duration, and puberty. Arch Dis Child 2005: 90: 411-414.
21. Umpierrez GE, Latif KA, Murphy MB et al. Thyroid dysfunction in patients with type 1 diabetes: A longitudinal study. Diabetes Care 2003: 26: 1181-1185.
22. Aktay AN, Lee PC, Kumar V, Parton E, Wyatt DT, Werlin SL. The prevalence and clinical characteristics of celiac disease in juvenile diabetes in Wisconsin. J Pediatr Gastroenterol Nutr 2001: 33: 462-465.
23. Calero P, Ribes-Koninckx C, Albiach V, Carles C, Ferrer J. IgA antigliadin antibodies as a screening method for nonovert celiac disease in children with insulin-dependent diabetes mellitus. J Pediatr Gastroenterol Nutr 1996: 23: 29-33.
24. Carlsson AK, Axelsson IE, Borulf SK et al. Prevalence of IgA-antiendomysium and IgA-antigliadin autoantibodies at diagnosis of insulin-dependent diabetes mellitus in Swedish children and adolescents. Pediatrics 1999: 103: 1248-1252.
25. Crone J, Rami B, Huber WD, Granditsch G, Schober E. Prevalence of celiac disease and follow-up of EMA in children and adolescents with type 1 diabetes mellitus. J Pediatr Gastroenterol Nutr 2003: 37: 67-71.
26. De Vitis I, Ghirlanda G, Gasbarrini G. Prevalence of coeliac disease in type I diabetes: A multicentre study. Acta Paediatr Suppl 1996: 412: 56-57.
27. Hansen D, Bennedbaek FN, Hansen LK et al. High prevalence of coeliac disease in Danish children with type I diabetes mellitus. Acta Paediatr 2001: 90: 1238-1243 (Comment).
28. Not T, Tommasini A, Tonini G et al. Undiagnosed coeliac disease and risk of autoimmune disorders in subjects with type I diabetes mellitus. Diabetologia 2001: 44: 151-155.
29. Smith CM, Clarke CF, Porteous LE, Elsori H, Cameron DJ. Prevalence of coeliac disease and longitudinal follow-up of antigliadin antibody status in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes 2000: 1: 199-203.
30. Westman E, Ambler GR, Royle M, Peat J, Chan A. Children with coeliac disease and insulin dependent diabetes mellitus - growth, diabetes control and dietary intake. J Pediatr Endocrinol Metab 1999: 12: 433-442.
31. Saukkonen T, Vaisanen S, Akerblom HK, Savilahti E. Childhood diabetes in Finland Study Group: Coeliac disease in children and adolescents with type 1 diabetes: A study of growth, glycaemic control, and experiences of families. Acta Paediatr 2002: 91: 297-302.
32. Mohn A, Cerruto M, Lafusco D et al. Celiac disease in children and adolescents with type I diabetes: Importance of hypoglycemia. J Pediatr Gastroenterol Nutr 2001: 32: 37-40.
33. Tesei N, Sugai E, Vazquez H et al. Antibodies to human recombinant tissue transglutaminase may detect coeliac disease patients undiagnosed by endomysial antibodies. Aliment Pharmacol Ther 2003: 17: 1415-1423.
34. Lenhardt A, Plebani A, Marchetti F et al. Role of human-tissue transglutaminase IgG and anti-gliadin IgG antibodies in the diagnosis of coeliac disease in patients with selective immunoglobulin A deficiency. Dig Liver Dis 2004: 36: 730-734.
35. Cataldo F, Marino V, Bottaro G, Greco P, Ventura A. Celiac disease and selective immunoglobulin A deficiency. J Pediatr 1997: 131: 306-308.
36. Marsh MN, Crowe PT. Morphology of the mucosal lesion in gluten sensitivity. Baillieres Clin Gastroenterol 1995: 9: 273-293.
37. Amin R, Murphy N, Edge J, Ahmed ML, Acerini CL, Dunger DB. A longitudinal study of the effects of a gluten-free diet on glycemic control and weight gain in subjects with type 1 diabetes and celiac disease. Diabetes Care 2002: 25: 1117-1122.
38. Acerini CL, Ahmed ML, Ross KM, Sullivan PB, Bird G, Dunger DB. Coeliac disease in children and adolescents with IDDM: Clinical characteristics and response to gluten-free diet. Diabet Med 1998: 15: 38-44.
39. Corazza GR, Di Sario A, Cecchetti L et al. Influence of pattern of clinical presentation and of gluten-free diet on bone mass and metabolism in adult coeliac disease. Bone 1996: 18: 525-530.
40. Fabiani E, Catassi C, Villari A et al. Dietary compliance in screening-detected coeliac disease adolescents. Acta Paediatr Suppl 1996: 412: 65-67.
41. Mustalahti K, Collin P, Sievanen H, Salmi J, Maki M. Osteopenia in patients with clinically silent coeliac disease warrants screening. Lancet 1999: 354: 744-745.
42. Cerutti F, Bruno G, Chiarelli F, Lorini R, Meschi F, Sacchetti C. Younger age at onset and sex predict celiac disease in children and adolescents with type 1 diabetes: An Italian multicenter study. Diabetes Care 2004: 27: 1294-1298.
43. Handa S, Dogra S. Epidemiology of childhood vitiligo: A study of 625 patients from north India. Pediatr Dermatol 2003: 20: 207-210.
44. Verrotti A, Chiarelli F, Amerio PL, Morgese G. Skin diseases in children with type 1 diabetes mellitus. J Eur Acad Dermatol Venereol 1995: 4: 41-43.
45. Falorni A, Laureti S, Nikoshkov A et al. 21-hydroxylase autoantibodies in adult patients with endocrine autoimmune diseases are highly specific for Addison's disease. Belgian Diabetes Registry. Clin Exp Immunol 1997: 107: 341-346.
46. Peterson P, Salmi H, Hyoty H et al. Steroid 21-hydroxylase autoantibodies in insulin-dependent diabetes mellitus. Childhood Diabetes in Finland (DiMe) Study Group. Clin Immunol Immunopathol 1997: 82: 37-42.
47. Aaltonen J, Bjorses P, Sandkuijl L, Perheentupa J, Peltonen L. An autosomal locus causing autoimmune disease: Autoimmune polyglandular disease type I assigned to chromosome 21. Nat Genet 1994: 8: 83-87.
48. Ahonen P, Myllarniemi S, Sipila I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990: 322: 1829-1836.
49. Dittmar M, Kahaly GJ. Polyglandular autoimmune syndromes: Immunogenetics and long-term follow-up. J Clin Endocrinol Metab 2003: 88: 2983-2992.
50. Chatila TA, Blaeser F, Ho N et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 2000: 106: R75-R81.
51. Ampudia-Blasco FJ, Girbes J, Carmena R. A case of lipoatrophy with insulin glargine: Long-acting insulin analogs are not exempt from this complication. Diabetes Care 2005: 28: 2983.
52. Ampudia-Blasco FJ, Hasbum B, Carmena R. A new case of lipoatrophy with lispro insulin in insulin pump therapy: Is there any insulin preparation free of complications? Diabetes Care 2003: 26: 953.
53. Griffin ME, Feder A, Tamborlane WV. Lipoatrophy associated with lispro insulin in insulin pump therapy: An old complication, a new cause? Diabetes Care 2001: 24: 174.
54. Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes 1996: 104: 106-110.
55. Kordonouri O, Lauterborn R, Deiss D. Lipohypertrophy in young patients with type 1 diabetes. Diabetes Care 2002: 25: 634.
56. Saez-De-Ibarra L, Gallego F. Factors related to lipohypertrophy in insulin-treated diabetic patients: Role of educational intervention. Pract Diabetes Int 1998: 15: 9-11.
57. Johansson UB, Amsberg S, Hannerz L et al. Impaired absorption of insulin aspart from lipohypertrophic injection sites. Diabetes Care 2005: 28: 2025-2027.
58. Thow JC, Johnson AB, Marsden S, Taylor R, Home PD. Morphology of palpably abnormal injection sites and effects on absorption of isophane(NPH) insulin. Diabet Med 1990: 7: 795-799.
59. De Silva BD, Schofield OMV, Walker JD. The prevalence of necrobiosis lipoidica diabeticorum in children with type 1 diabetes. Br J Dermatol 1999: 141: 593-594.
60. Kelly WF, Nicholas J, Adams J, Mahmood R. Necrobiosis lipoidica diabeticorum: Association with background retinopathy, smoking, and proteinuria. A case controlled study. Diabet Med 1993: 10: 725-728.
61. Verrotti A, Chiarelli F, Amerio P, Morgese G. Necrobiosis lipoidica diabeticorum in children and adolescents: A clue for underlying renal and retinal disease. Pediatr Dermatol 1995: 12: 220-223.
62. Boyd AS. Tretinoin treatment of necrobiosis lipoidica diabeticorum. Diabetes Care 1999: 22: 1753-1754.
63. D'Argento V, Curatolli G, Filotico R, Foti C, Vena GA. Cyclosporin A in the treatment of necrobiosis lipoidica diabeticorum. J Dermatolog Treat 1997: 8: 123-125.
64. Evans AV, Atherton DJ. Recalcitrant ulcers in necrobiosis lipoidica diabeticorum healed by topical granulocyte-macrophage colony-stimulating factor. Br J Dermatol 2002: 147: 1023-1025.
65. Ling TC, Thomson KF, Goulden V, Goodfield MJ. PUVA therapy in necrobiosis lipoidica diabeticorum. J Am Acad Dermatol 2002: 46: 319-320.
66. Moreno-Arias GA, Camps-Fresneda A. Necrobiosis lipoidica diabeticorum treated with the pulsed dye laser. J Cosmet Laser Ther 2001: 3: 143-146.
67. Nguyen K, Washenik K, Shupack J. Necrobiosis lipoidica diabeticorum treated with chloroquine. J Am Acad Dermatol 2002: 46: S34-S36.
68. Stephens E, Robinson JA, Gottlieb P. Becaplermin and necrobiosis lipoidicum diabeticorum: Results of a case control pilot study. J Diabetes Complications 2001: 15: 55-56.
69. Tidman M. Management of necrobiosis lipoidica. Clin Exp Dermatol 2002: 27: 328-337.
70. Grgic A, Rosenbloom AL, Weber FT, Giordano B, Malone JI, Shuster JJ. Joint contracture - common manifestation of childhood diabetes mellitus. J Pediatr 1976: 88: 584-588.
71. Rosenbloom AL, Silverstein JH, Lezotte DC, Riley WJ, Maclaren NK. Limited joint mobility in diabetes mellitus of childhood: Natural history and relationship to growth impairment. J Pediatr 1982: 101: 874-878.
72. Rosenbloom AL, Silverstein JH, Lezotte DC, Richardson K, Mc Callum M. Limited joint mobility in childhood diabetes mellitus indicates increased risk for microvascular disease. N Engl J Med 1981: 305: 191-194.
73. Hanna W, Friesen D, Bombardier C, Gladman D, Hanna A. Pathologic features of diabetic thick skin. J Am Acad Dermatol 1987: 16: 546-553.
74. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986: 314: 403-408.
75. Garg SK, Chase HP, Marshall G et al. Limited joint mobility in subjects with insulin dependent diabetes mellitus: Relationship with eye and kidney complications. Arch Dis Child 1992: 67: 96-99.
76. Starkman HS, Gleason RE, Rand LI, Miller DE, Soeldner JS. Limited joint mobility (LJM) of the hand in patients with diabetes mellitus: Relation to chronic complications. Ann Rheum Dis 1986: 45: 130-135.
77. Silverstein JH, Gordon G, Pollock BH, Rosenbloom AL. Long-term glycemic control influences the onset of limited joint mobility in type 1 diabetes. J Pediatr 1998: 132: 944-947.
78. Infante JR, Rosenbloom AL, Silverstein JH, Garzarella L, Pollock BH. Changes in frequency and severity of limited joint mobility in children with type 1 diabetes mellitus between 1976-78 and 1998. J Pediatr 2001: 138: 33-37.
79. Lindsay JR, Kennedy L, Atkinson AB et al. Reduced prevalence of limited joint mobility in type 1 diabetes in a U.K. clinic population over a 20-year period. Diabetes Care 2005: 28: 658-661.
80. Hirshberg B, Muszkat M, Marom T, Shalit M. Natural course of insulin edema. J Endocrinol Invest 2000: 23: 187-188.
81. Wheatley T, Edwards OM. Insulin oedema and its clinical significance: metabolic studies in three cases. Diabet Med 1985: 2: 400-404.